Antiphospholipid Antibodies and Subsequent Thrombo-occlusive Events in Patients with Ischemic Stroke

JAMA

Volumn 291, Issue 5, 2004, Pages 576-584

  Levine, Steven R ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CARDIOLIPIN ANTIBODY; LUPUS ANTICOAGULANT; LUPUS ANTICOAGULANT ANTIBODY; PHOSPHOLIPID ANTIBODY; UNCLASSIFIED DRUG; WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG RESPONSE; FEMALE; HEART INFARCTION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; RISK; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; BLOOD; COHORT ANALYSIS; IMMUNOLOGY; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

AGED; ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ASPIRIN; CEREBROVASCULAR ACCIDENT; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS; THROMBOSIS; WARFARIN;

EID: 10744223871     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.291.5.576     Document Type: Article

References (42)

1. Gorelick PB, Alter M, eds. The Prevention of Stroke. New York, NY: The Parthenon Publishing Group; 2002.
2. Wolf PA, Clagett GP, Easton JD, et al. Preventing ischemic stroke in patients with prior stroke and transient ischemic attack: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke. 1999;30:1991-1994.
3. Petty G, Brown R, Whisnant J, et al. Survival and recurrence after first cerebral infarction: a population-based study in Rochester, Minnesota, 1975 through 1989. Neurology. 1998;50:208-216.
4. Lockshin MD. Antiphospholipid antibody: babies, blood clots, biology. JAMA. 1997;277:1549-1551.
5. Harris EN, Gharavi AE, Boey ML, et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet. 1983;2:1211-1214.
6. Antiphospholipid Antibodies in Stroke Study (APASS) Group. Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology. 1993;43:2069-2073.
7. Turhim S, Rand JH, Wu X, et al. Elevated anticardiolipin antibody titer is a stroke risk factor in a multiethnic population independent of isotype or degree of positivity. Stroke. 1999;30:1561-1565.
8. Nencini P, Baruffi MC, Abbate R, et al. Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischemia. Stroke. 1992;23:189-193.
9. Muir KW, Squire IB, Alwan W, et al. Anticardiolipin antibodies in an unselected stroke population. Lancet. 1994;344:452-456.
10. Metz LM, Edworthy S, Mydlarski R, Fritzler MJ. The frequency of phospholipid antibodies in an unselected stroke population. Can J Neurol Sci. 1998; 25:64-69.
11. Ginsburg KS, Liang MH, Newcomer L, et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med. 1992;117: 997-1002.
12. Brey RL, Abbott RD, Curb JD, et al. Beta-(2)-glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the Honolulu Heart Program. Stroke. 2001;32:1701-1706.
13. Brey RL, Stallworth CL, McGlasson DL, et al. Antiphospholipid antibodies and stroke in young women. Stroke. 2002;33:2396-2400.
14. Antiphospholipid Antibodies and Stroke Study Group (APASS). Anticardiolipin antibodies and the risk of recurrent thrombo-occlusive events and death. Neurology. 1997;48:91-94.
15. Tanne D, D'Olhaberriague L, Trivedi AM, et al. Anticardiolipin antibodies and mortality in patients with ischemic stroke: a prospective followup study. Neuroepidemiology. 2002;21:93-99.
16. Sletnes KE, Smith P, Abdelnoor M, et al. Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-haemorrhagic stroke. Lancet. 1992;339:451-453.
17. Rand JH, Wu X-X, Andree HAM, et al. Pregnancy loss in the antiphospholipid-antibody syndrome-a possible thrombogenic mechanism [published correction appears in N Engl J Med. 1997;337: 1327]. N Engl J Med. 1997;337:154-160.
18. Rand JH, Wu X-X, Andree HAM, et al. Pregnancy loss in the antiphospholipid-antibody syndrome-a possible thrombogenic mechanism [published correction appears in N Engl J Med. 1997;337: 1327]. N Engl J Med. 1997;337:154-160.
19. Roubey RAS, Hoffman M. From antiphospholipid syndrome to antibody-mediated thrombosis. Lancet. 1997;350:1491-1493.
20. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med. 2002;346:752-763.
21. Hojnik M, George J, Ziporen L, et al. Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation. 1996;93:1579-1587.
22. Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med. 1995;332:993-997.
23. WARSS, APASS, PICSS, and HAS Study Groups. The feasibility of a collaborative double-blind study using an anticoagulant: the Warfarin-Aspirin Recurrent Stroke Study (WARSS), the Antiphospholipid Antibodies And Stroke Study (APASS), the Patent foramen ovale In Cryptogenic Stroke Study (PICSS), and the Hemostatic system Activation Study (HAS). Cerebrovasc Dis. 1997;7:100-112.
24. Mohr JP, Thompson JLP, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stoke. N Engl J Med. 2001;345: 1444-1451.
25. WARSS Study Group. A double-blind study using an anticoagulant: the design and initial progress of the Warfarin-Aspirin Recurrent Stroke Study (WARSS). Cerebrovasc Dis. 1997;7:100-112.
26. Brandt JT, Bana LK, Triplett DA, on behalf of the Subcommittee on Lupus Anticoagulants/Antiphospholipid Antibodies of the ISTH. Laboratory identification of lupus anticoagulants: results of the Second Internatonal Workshop for Identification of Lupus Anticoagulants. Thromb Haemost. 1995;74:1597-1603.
27. Steinberg D, Colla P. CART: Tree-Structured Non-Parametric Data Analysis. San Diego, Calif: Salford Systems; 1995.
28. Harris EN. The second international anticardiolipin standardization workshop/the Kingston Antiphospholipid Antibody Study (KAPS) group. Am J Clin Pathol. 1990;94:476-484.
29. Harris EN, Pierangeli SS, Birch D. Anticardiolipin wet workshop report: fifth International Symposium on Antiphospholipid Antibodies. Am J Clin Pathol. 1994;101:616-624.
30. Brey I, Cote SA, McGlasson DL, et al. Effects of repeated freeze-thaw cycles on anticardiolipin antibody immunoreactivity. Am J Clin Pathol. 1994;102: 586-588.
31. Rosove MH, Brewer PMC. Antiphospholipid thombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med. 1992;117:303-308.
32. Krnic-Barrie S, O'Conor CR, Looney SW, et al. A retrospective review of 61 patients with antiphospholipid syndrome: analysis of factors influencing recurrent thrombosis. Arch Intem Med. 1997;157:2101-2108.
33. Ruiz Irastorza G, Khamashta MA, Hunt BJ, et al. Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. Arch Intern Med. 2002;162:1164-1169.
34. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003; 349:1133-1138.
35. Sanmarco M, Soler C, Christids C, et al. Prevalence and clinical significance of IgG isotype antibeta 2-glycoprotein I antibodies in antiphospholipid syndrome: a comparative study with anticardiolipin antibodies. J Lab Clin Med. 1997;129:499-506.
36. Cabral AR, Amigo MC, Cabiedes J, et al. The antiphospholipid/cofactor syndromes; a primary variant with antibodies to β2-glycoprotein I but no antibodies detectable in standard antiphospholipid assays. Am J Med. 1996;101:472-481.
37. Turhim S, Rand JH, Goldman M, et al. Antiphosphatidylserine antibodies are independently associated with ischemic stroke. Neurology. 1999;53:1523-1527.
38. Brandt JT, Triplett DA, Alving B, et al, on behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardization Committee of the ISTH. Criteria for the diagnosis of the lupus anticoagulants: an update. Thromb Haemost. 1995;74:1185-1190.
39. Galli M, Dlott J, Norbis F, et al. Lupus anticoagulants and thrombosis: clinical association of different coagulation and immunologic tests. Thromb Haemost. 2000;84:1012-1016.
40. Tripodi A, Biasiolo A, Chantarangkul V, et al. Lupus anticoagulant (LA) testing: performance of clinical laboratories assessed by a national survey using lyophilized affinity-purified immunoglobulin with LA activity. Clin Chem. 2003;49:1608-1614.
41. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999;42:1309-1311.
42. Wilson WA, Gharavi AE, Piette J-C. International classification criteria for antiphospholipid syndrome: synopsis of a post-conference workshop held at the Ninth International (Tours) aPL Symposium. Lupus. 2001;10:457-460.